Patents by Inventor Cynthia J. Galloway

Cynthia J. Galloway has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7695675
    Abstract: A method of inactivating microorganisms such as viruses within a fluid such as a biological fluid is disclosed. The method includes the steps of providing a UV reactor, which may take the form of an elongated generally annular reaction chamber surrounding at least one elongated UV lamp, moving the fluid within the reaction chamber in a primary flow directed along the length of the UV lamp, and inducing a circulating secondary flow within the fluid with the secondary flow being superimposed on the primary flow. As the fluid moves through the reaction chamber in the primary flow, it is circulated repeatedly toward and away from the UV lamp in the circulating secondary flow to provide uniform and controllable exposure of the entire volume of fluid to ultraviolet radiation. Microorganisms such as viruses are thus inactivated while desirable components in the fluid, such as proteins, are preserved without the use of a free radical scavenger.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: April 13, 2010
    Assignees: Bayer Healthcare LLC, Bayer Aktiengesellschaft
    Inventors: Klaus Kaiser, Hans-Juergen Henzler, Joerg Kauling, Rolf Treckmann, Kathryn Remington, Cynthia J. Galloway
  • Publication number: 20030049809
    Abstract: A method of inactivating microorganisms such as viruses within a fluid such as a biological fluid is disclosed. The method includes the steps of providing a UV reactor, which may take the form of an elongated generally annular reaction chamber surrounding at least one elongated UV lamp, moving the fluid within the reaction chamber in a primary flow directed along the length of the UV lamp, and inducing a circulating secondary flow within the fluid with the secondary flow being superimposed on the primary flow. As the fluid moves through the reaction chamber in the primary flow, it is circulated repeatedly toward and away from the UV lamp in the circulating secondary flow to provide uniform and controllable exposure of the entire volume of fluid to ultraviolet radiation. Microorganisms such as viruses are thus inactivated while desirable components in the fluid, such as proteins, are preserved without the use of a free radical scavenger.
    Type: Application
    Filed: July 16, 2002
    Publication date: March 13, 2003
    Inventors: Klaus Kaiser, Hans-Juergen Henzler, Joerg Kauling, Rolf Treckmann, Kathryn Remington, Cynthia J. Galloway
  • Patent number: 5786458
    Abstract: A process for viral inactivation of a solution containing a biologically active protein, wherein the process comprises the steps of 1) contacting the solution with an immobilized ligand under conditions which allow protein to bind to the ligand, 2) subjecting the bound protein to a viral inactivation method under conditions which would result in substantial denaturation of the protein if it were not bound to the ligand, and 3) recovering the protein by washing the immobilized protein under conditions which favor the release of the protein into the solution under conditions in which the recovered protein retains its biological activity.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: July 28, 1998
    Assignee: Bayer Corporation
    Inventors: George A. Baumbach, David J. Hammond, John M. Lang, Cynthia J. Galloway
  • Patent number: 5658746
    Abstract: A method of controlling the amount of a biologically active substance binding to a cell surface having both receptors to the substance and receptors for the Fc domain of an antibody that can complex with the substance or other antibodies that can complex with the substance. By exploiting the generally more numerous Fc receptor sites, substance binding can be increased and/or controlled. Method contemplates controlling amounts of substances such as cytokines, hormones, and growth factors that are associated with cells such as monocytes, macrophages, granulocytes, B cells, T cells, and platelets. Method is illustrated using conjugated antibodies to tissue necrosis factor (TNF) to increase the binding of TNF to monocytes.
    Type: Grant
    Filed: November 3, 1995
    Date of Patent: August 19, 1997
    Assignee: Bayer Corporation
    Inventors: Michael H. Coan, Cynthia J. Galloway, Vivian W. Lee